Influence of G1359A polimorphysm of the cannabinoid receptor gene (CNR1) on insulin resistance and adipokines in patients with non alcoholic fatty liver disease,;Influencia del polimorfismo G1359A del gen del receptor cannabinoide (CNR1) sobre la resistencia a la insulina y adipocinas en pacientes con enfermedad hepatica no alcohólica

Nutricion Hospitalaria

Volumn 27, Issue 5, 2012, Pages 1637-1642

  Aller, R ^a   de Luis, D A ^a   Pacheco, D ^a   Velasco, M C ^a   Conde, R ^a   Izaola, O ^a   Gonzalez Sagrado M ^a  

^a UNIVERSITY OF VALLADOLID   (Spain)

Author keywords

Adipokines; Cannabinoid receptor gene; Insulin resistance; Polymorphism; Steatosis

Indexed keywords

ADIPOCYTOKINE; CANNABINOID 1 RECEPTOR; GLUCOSE BLOOD LEVEL;

ADULT; ANTHROPOMETRY; BIOPSY; BLOOD; BODY WEIGHT; ENZYMOLOGY; FATTY LIVER; FEMALE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; LIVER; MALE; METABOLISM; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; PATHOLOGY; PHYSIOLOGY; POLYMERASE CHAIN REACTION;

ADIPOKINES; ADULT; ANTHROPOMETRY; BIOPSY; BLOOD GLUCOSE; BODY WEIGHT; FATTY LIVER; FEMALE; GENOTYPE; HUMANS; INSULIN RESISTANCE; LIVER; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RECEPTOR, CANNABINOID, CB1;

EID: 84867457617     PISSN: 02121611     EISSN: 16995198     Source Type: Journal    
DOI: 10.3305/nh.2012.27.5.6011     Document Type: Article

References (32)

1. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clinic Proc 1980; 55: 434-438.
2. Kral JG, Schaffner F, Pierson RN, Wang J. Body fat topography as an independent predictor of fatty liver. Metabolism 1993; 42: 548-551.
3. Mallat A, Lotersztajn S. Endocannabinoids and their role in fatty liver disease. 2010; 28 (1): 261-266.
4. Matsuzawa Y. Adipocytokines: Emerging therapeutic targets. Current Atherosclerosis Reports 2005; 7: 58-62.
5. Smart RG, Ogborne AC. Drug use and drinking among students in 36 countries. Addict Behav 2000; 25: 455-460.
6. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946-1949.
7. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006; 58: 389-462.
8. Mukhopadhyay P, Bátkai S, Rajesh M, Czifra N, Harvey-White J, Haskó G et al. Pharmacological inhibition of CB1 cannabi-noid receptor protects against doxorubicin-induced cardiotoxicity. J Am Coll Cardiol 2007; 50: 528-36. doi: 10.1016/j.jacc.2007.03.057.
9. Gadzicki D, Muller-Vahl K, Stuhrmann M. A frequent polymorphism in the coding exon of the human cannabinoid receptor (CNR1) gene. Mol Cell Probes 1999; 13: 321-323.
10. Brunt EM. Non alcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001; 21: 3-16.
11. Duart MJ, Arroyo CO, Moreno JL. Validation of a insulin model for the reactions in RIA. Clin Chem Lab Med 2002; 40: 1161-1167.
12. Mathews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF. Homesotasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-414.
13. Pfutzner A, Langefeld M, Kunt T, Lobig M. Evaluation of human resistin assays with serum from patients with type 2 diabetes and different degrees of insulin resistance. Clin Lab 2003; 49: 571-576.
14. Meier U, Gressner M. Endocrine regulation of energy metabolis: review of pathobiochemical and clinical chemical aspects of leptin, Ghrelin, adiponectin, and resistin. Clin Chem 2004; 50: 1511-1525.
15. Suominen P. evaluation of an enzyme immunometric assay to measure serum adiponectin concentrations. Clin Chem 2004; 50: 219-221.
16. Lubrano V, Cocci F, Battaglia D, Papa A. Usefulness of high - sensitivity IL6 measurmentfor clinical characterization of patients with coronary artery disease. J Clin Lab Anal 2005; 19: 110-114.
17. Khan SS, Smith MS, reda D, Suffredini AF, Mc Coy JP. Multiplex bead array assays for detection of soluble cytokines: comparisons of sensitivity and quantitative values among kits from multiple manufactures. Cytometry B Clin Cytom 2004; 61: 35-39.
18. Pichard C, Slosman D, Hirschel B, Kyle U. Bioimpedance analysis: an improved method for nutritional follow up. Clin Res 1993; 41: 53.
19. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T, Kunos G. Leptin. Regulated endocannabinoids are involved in maintaining food intake. Nature 2001; 410: 822-825.
20. Osei-Hyiaman D, Liu J, Zhou L, Godlewski G, Harvey-White J, Jeong W, Batkai S, Marsicano G, Lutz B, Buettner C, Kunos G. Hepatic CB1 receptor is required for development of diet -induced steatosis, dyslipidemia, and sinsulin and leptin resitance in mice. J Clin Invest 2008; 118: 3160-3169.
21. Jourdan T, Djaouti L, Demizieux L, Gresti J, Verges B, Degrace P. CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat aand reverses liver steatosis in diet-induced obese mice.
22. Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm, C, Schubert M, Auer D, Yassouridis A, Thone-Reineke C, Pasquali R, Lutz B, Stalla GK, Pagotto U. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003; 112: 423-431.
23. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Batkai S, Harvey-White J, Mackie K, Offertaler L, Wang, L, Kunos G. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005; 115: 1298-1305.
24. Ravinet TC, Delgorge C, Menet C, Arnone M, Soubrie P. CB1 cannabinoid receptor knockout in mice leads to leannes, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 2004;28:640-648.
25. Gazzerro P, Caruso MG, Notarnicola M, Misciagna G, Guerra V, Laezza C, Bifulco M. Association between cannabinoid type 1 receptor polymorphism and body mass index in a southern Italian population. Int J Obes 2007; 31: 908-912.
26. De Luis DA, González Sagrado M, Aller R, Izaola O, Conde R. Influence of g139A polymorphism of the cannabinoid receptor gener (CNR1) on antrhopometric parameters and insulin resitance in females with obesity.
27. Anna Parfieniuk, Robert Flisiak Role of cannabinoids in chronic liver diseases. World J Gastroenterol 2008; 14: 6109-6114.
28. Pagano C, Marin O, Calcagno A, Schiappelli P, Pilon C, Milan G et al. Increased serum resistin in adults with Prader Willi syndrome is related to obesity and not to insulin resistance. J Clin Endocrinol Metab 2005; 90: 4335-4340.
29. Burnett MS, Devaney JM, Adenika RJ, Lindsay R, Howard BV. Cross-sectional associations of resistin, coronary he art disease and insulin resistance. J Clin Endocrinol Metab 2006; 91: 64-68.
30. Zou CC, Liang L, Hong F, Fu JF, Zhao ZY. Serum adiponectin, resistin levels and non alcoholic fatty liver disease in obese children. Endocr J 2005; 52: 519-524.
31. Ognjanovic S. Genomic organization of the gene coding for human pre-Bcell colony enhancing factor and expression in human fetal membranes. J Mol Endocrinol 2001; 26: 107-117.
32. De Luis DA, González Sagrado M, Aller R, Conde R, Izaola O. Circulating visfatin in obese non-diabetic patients in relation to cardiovascular risk factors, insulin resistance, and adipocytokines: A contradictory piece of the puzzle. Nutrition 2010; 1130-1133.